<DOC>
	<DOCNO>NCT01194830</DOCNO>
	<brief_summary>Study linagliptin vs. placebo Black/African American patient T2DM MTT sub-study</brief_summary>
	<brief_title>Efficacy Safety Linagliptin ( BI 1356 ) Black/African Americans With Type 2 Diabetes With MTT Sub-study</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : 1 . Dated write informed consent accordance GCP local legislation . 2 . Male female Black / African American patient 3 . Diagnosis type 2 diabetes least 3 month prior inform consent . 4 . HbA1c equal 7.5 % less equal 11 % Visit 1 . 5 . Patients currently treatmentnaive treat one oral antidiabetic medication . Antidiabetic medication unchanged least 10 week prior inform consent . 6 . Age 18 le 80 year Visit 1 ( Screening ) . 7 . BMI ( Body Mass Index ) less 45 kg/m2 Visit 1 . Exclusion criterion : 1 . Myocardial infarction ( MI ) , stroke transient ischemic attack ( TIA ) within 3 month inform consent . 2 . Type 1 diabetes . 3 . Impaired hepatic function , define serum level either alanine aminotransferase ( ALT , SGPT ) , aspartate aminotransferase ( AST , SGOT ) , alkaline phosphatase 3 x upper limit normal ( ULN ) determine Visit 1 . 4 . Known prior hypersensitivity allergy investigational product excipients . 5 . Treatment insulin within 3 month prior inform consent . 6 . Treatment antiobesity drug ( e.g. , sibutramine , orlistat , rimonabant ) within three month prior inform consent initiate therapy study . 7 . Any prior use dipeptidyl peptidase4 ( DPP4 ) inhibitor . 8 . Glucagonlike peptide1 ( GLP1 ) agonists exclude 3 month prior inform consent . 9 . History alcohol drug abuse within 3 month prior inform consent would interfere trial participation assess Investigator . 10 . Participation another trial investigational drug within 3 month prior inform consent study . 11 . Premenopausal woman ( last menstruation less 1 year prior informed consent ) : nursing pregnant surgically sterile childbearing potential practicing acceptable method birth control plan continue use method throughout study agree submit periodic pregnancy test participation trial . Acceptable method birth control include transdermal patch , intrauterine devices/systems ( IUDs / IUSs ) , oral , implantable injectable contraceptive , vasectomised partner . No exception make . Hormonal birth control use least three month prior sign inform consent continue least next menstrual period complete study . 12 . Current treatment chronic use systemic steroid time informed consent change dosage thyroid hormone within 6 week prior inform consent . 13 . History bariatric surgery . 14 . Patients demonstrate inability compliant ( 80120 % ) dose regimen placebo runin period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>